Market Cap 497.62B
Revenue (ttm) 88.82B
Net Income (ttm) 14.07B
EPS (ttm) N/A
PE Ratio 19.26
Forward PE 18.40
Profit Margin 15.84%
Debt to Equity Ratio 0.50
Volume 6,866,196
Avg Vol 8,684,448
Day's Range N/A - N/A
Shares Out 2.41B
Stochastic %K 89%
Beta 0.36
Analysts Strong Sell
Price Target $206.29

Company Profile

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of various products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 732 524 0400
Website: www.jnj.com
Address:
One Johnson & Johnson Plaza, New Brunswick, United States
Pearl_Power
Pearl_Power Dec. 12 at 9:44 PM
$JNJ weekly. up up up
0 · Reply
mikesterz7
mikesterz7 Dec. 12 at 9:38 PM
$MRNA $PFE $JNJ $AZN 🤣🤣🤣
0 · Reply
_MoonSwinger
_MoonSwinger Dec. 12 at 9:15 PM
0 · Reply
iwtd
iwtd Dec. 12 at 8:30 PM
$JNJ - I made a video on this stock 2 weeks ago. The price at that time was 203$. Today the stock is 211$. That is a price increase of 8% in 2 weeks. Not bad. https://youtu.be/k94Zcp4zjnM?si=glSAr6x9qkvYnp4j
0 · Reply
peloswing
peloswing Dec. 12 at 7:53 PM
$JNJ at the very least, will see a short-term rejection at this trendline.
0 · Reply
Stocktrader3546
Stocktrader3546 Dec. 12 at 7:31 PM
$JNJ jnj just doesnt care lol, this is going to 2020 easy. if all this market selling has no impact..
0 · Reply
barretramsden8
barretramsden8 Dec. 12 at 7:27 PM
$XOM $JNJ $PLTR $BABA The target price has been raised, sending a positive signal.
0 · Reply
AStrokeOfLuck
AStrokeOfLuck Dec. 12 at 7:20 PM
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Dec. 12 at 6:52 PM
Enter: $JNJ Calls Strike Price: $210 Expiry Date: JAN 02 2026 Buy in Price: $3.00 - $4.00 Sell Price: $6.36 Profit : +112% (Turn every $1 into $2.12) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us
0 · Reply
JarvisFlow
JarvisFlow Dec. 12 at 5:26 PM
Morgan Stanley has updated their rating for Johnson & Johnson ( $JNJ ) to Equal-Weight with a price target of 197.
0 · Reply
Latest News on JNJ
Johnson & Johnson: Reliable Cash Flows, Moderate Expectations

Dec 11, 2025, 7:05 PM EST - 21 hours ago

Johnson & Johnson: Reliable Cash Flows, Moderate Expectations


16 Quality Stocks to Own for a Volatile Market

Dec 1, 2025, 1:23 PM EST - 11 days ago

16 Quality Stocks to Own for a Volatile Market

CSCO LLY XOM


2 Top Dividend Stocks to Buy and Hold

Nov 30, 2025, 4:05 AM EST - 12 days ago

2 Top Dividend Stocks to Buy and Hold

BMY


Best Dividend Aristocrats For December 2025

Nov 29, 2025, 8:02 AM EST - 13 days ago

Best Dividend Aristocrats For December 2025

ABBV ABT ADM ADP AFL ALB AMCR


Dogs Of The Dow Continue Outperforming Broader Market

Nov 29, 2025, 1:45 AM EST - 13 days ago

Dogs Of The Dow Continue Outperforming Broader Market

AMGN DIA MAGS SPY


Wasatch Global Value Fund Q3 2025 Performance Review

Nov 28, 2025, 7:50 AM EST - 14 days ago

Wasatch Global Value Fund Q3 2025 Performance Review

BABA CNC DOX NVDA


3 Superb Dividend Stocks to Hold for the Next 20 Years

Nov 27, 2025, 6:30 AM EST - 15 days ago

3 Superb Dividend Stocks to Hold for the Next 20 Years

KO O


1 Reason Why Shares of Johnson & Johnson Are Surging This Month

Nov 21, 2025, 12:43 PM EST - 21 days ago

1 Reason Why Shares of Johnson & Johnson Are Surging This Month


Why Johnson & Johnson's Share Price Is Popping This Month

Nov 19, 2025, 12:24 PM EST - 23 days ago

Why Johnson & Johnson's Share Price Is Popping This Month


Johnson & Johnson to Buy Halda Therapeutics For $3.05 Billion

Nov 17, 2025, 8:29 AM EST - 25 days ago

Johnson & Johnson to Buy Halda Therapeutics For $3.05 Billion


Halda Therapeutics Announces Acquisition by Johnson & Johnson

Nov 17, 2025, 8:15 AM EST - 25 days ago

Halda Therapeutics Announces Acquisition by Johnson & Johnson


Bristol Myers, J&J halt heart drug trial after interim review

Nov 14, 2025, 8:03 AM EST - 4 weeks ago

Bristol Myers, J&J halt heart drug trial after interim review

BMY


2 Strong Healthcare Stock Picks for Dividend Investors

Nov 13, 2025, 3:55 AM EST - 4 weeks ago

2 Strong Healthcare Stock Picks for Dividend Investors

ABBV


Johnson & Johnson: Dividends Don't Lie

Nov 7, 2025, 5:40 AM EST - 5 weeks ago

Johnson & Johnson: Dividends Don't Lie


Cramer's Mad Dash: Johnson & Johnson

Nov 6, 2025, 9:54 AM EST - 5 weeks ago

Cramer's Mad Dash: Johnson & Johnson


US FDA expands use of J&J's Caplyta as add-on depression drug

Nov 6, 2025, 7:34 AM EST - 5 weeks ago

US FDA expands use of J&J's Caplyta as add-on depression drug


Best Dividend Aristocrats For November 2025

Nov 1, 2025, 10:25 AM EDT - 5 weeks ago

Best Dividend Aristocrats For November 2025

ABBV ABT ADM ADP AMCR AOS ATO


Pearl_Power
Pearl_Power Dec. 12 at 9:44 PM
$JNJ weekly. up up up
0 · Reply
mikesterz7
mikesterz7 Dec. 12 at 9:38 PM
$MRNA $PFE $JNJ $AZN 🤣🤣🤣
0 · Reply
_MoonSwinger
_MoonSwinger Dec. 12 at 9:15 PM
0 · Reply
iwtd
iwtd Dec. 12 at 8:30 PM
$JNJ - I made a video on this stock 2 weeks ago. The price at that time was 203$. Today the stock is 211$. That is a price increase of 8% in 2 weeks. Not bad. https://youtu.be/k94Zcp4zjnM?si=glSAr6x9qkvYnp4j
0 · Reply
peloswing
peloswing Dec. 12 at 7:53 PM
$JNJ at the very least, will see a short-term rejection at this trendline.
0 · Reply
Stocktrader3546
Stocktrader3546 Dec. 12 at 7:31 PM
$JNJ jnj just doesnt care lol, this is going to 2020 easy. if all this market selling has no impact..
0 · Reply
barretramsden8
barretramsden8 Dec. 12 at 7:27 PM
$XOM $JNJ $PLTR $BABA The target price has been raised, sending a positive signal.
0 · Reply
AStrokeOfLuck
AStrokeOfLuck Dec. 12 at 7:20 PM
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Dec. 12 at 6:52 PM
Enter: $JNJ Calls Strike Price: $210 Expiry Date: JAN 02 2026 Buy in Price: $3.00 - $4.00 Sell Price: $6.36 Profit : +112% (Turn every $1 into $2.12) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us
0 · Reply
JarvisFlow
JarvisFlow Dec. 12 at 5:26 PM
Morgan Stanley has updated their rating for Johnson & Johnson ( $JNJ ) to Equal-Weight with a price target of 197.
0 · Reply
Deeznutsswapmeet
Deeznutsswapmeet Dec. 12 at 4:46 PM
$JNJ $KVUE Still spamming… check this clown’s posts. Stop posting hot takes with no credibility. Find a new hobby and @Stocktwits ban this type of garbage poster.
0 · Reply
Jhoooon
Jhoooon Dec. 12 at 3:15 PM
$BMEA is the upcoming game changer in the Diabetes and obesity market. Eli Lilly ($LLY) has become the first healthcare company to reach a market capitalization of $1 trillion, thanks to soaring demand for its obesity and diabetes medications, which now account for more than half of its total revenue. The success of GLP-1 treatments like Mounjaro and Zepbound has driven Eli Lilly's stock price up more than 37% since the beginning of the year. Meanwhile, competitors like Novo Nordisk $NVO and Johnson & Johnson $JNJ have seen their market capitalizations grow more slowly, even as they have expanded their product portfolios in the metabolic health space. Will the competition be able to catch up? 💊 My answer is yes, if they can BUY OUT a game changer like BIOMEA $BMEA . And this should not be too long now...🎉
0 · Reply
abishop717
abishop717 Dec. 12 at 2:42 PM
$CAT $GS $JNJ $IBM 🔥🔥🔥🔥🔥🔥🔥🔥🔥🔥 🤌🤌🤌🤌🤌🤌🤌🤌🤌🤌 🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀
0 · Reply
Jhoooon
Jhoooon Dec. 12 at 2:42 PM
$BMEA $NVO $LLY $JNJ the more Lilly dominates the more desperate competitors will be to acquire differentiating science This renders BMEA a prime target
0 · Reply
abishop717
abishop717 Dec. 12 at 2:40 PM
Stilllll holdinggggg $JNJ
0 · Reply
Quantumup
Quantumup Dec. 12 at 12:49 PM
Citizens reiterated $PTGX Market Outperform/$102. $TAK $JNJ Citizens said in its note: PTGX has a big decision coming up by mid-2026 when management has to determine whether to opt out of its 50/50 U.S. profit/loss share for rusfertide with Takeda, which would change PTGX's downstream economics. We assume PTGX will opt out to bring in more risk-free cash that the company can deploy to advance its earlier-stage internal pipeline.
0 · Reply
Jhoooon
Jhoooon Dec. 12 at 8:45 AM
$NVO $LLY $JNJ $BMEA Eli Lilly ($LLY) has become the first healthcare company to reach a market capitalization of $1 trillion, thanks to soaring demand for its obesity and diabetes medications, which now account for more than half of its total revenue. The success of GLP-1 treatments like Mounjaro and Zepbound has driven Eli Lilly's stock price up more than 37% since the beginning of the year. Meanwhile, competitors like Novo Nordisk $NVO and Johnson & Johnson $JNJ have seen their market capitalizations grow more slowly, even as they have expanded their product portfolios in the metabolic health space. Will the competition be able to catch up? 💊 My answer is yes, if they can BUY OUT a game changer like BIOMEA $BMEA . And this should not be too long now...🎉
0 · Reply
Timetoflytothemoon
Timetoflytothemoon Dec. 11 at 11:47 PM
$ASBP $IXHL both get a BO from $JNJ i would have to get a new girlfriend!
1 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 11 at 10:26 PM
Actionable Trade Alert for $JNJ: Market Context: $JNJ closed at $210.8, showing strong momentum with an RSI of 66.75, indicating near overbought conditions. The stock is trading above its 30-day MA of $198.47 and 50-day MA of $195.21, suggesting bullish sentiment. Directional Bias: The recent high of $211.23 indicates potential resistance, while the 60-day low of $173.33 provides a solid support base. The current price is near the high end of this range, and the upward trend supported by moving averages suggests further upside potential. Trade Plan: - Suggested Entry: $210.8 - Stop Loss: $204.0 (risking $6.8) - Take Profit Targets: 1. $215.0 (2% gain) 2. $220.0 (4.5% gain) 3. $246.0 (17% gain) This plan targets a minimum of 17% ROI on the third take profit. Monitor the trade closely, especially with the RSI nearing overbought levels. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
Xandrelithorne
Xandrelithorne Dec. 11 at 9:33 PM
$JNJ healthcare majors offering balanced tape support
0 · Reply
JarvisFlow
JarvisFlow Dec. 11 at 9:05 PM
Citigroup updates rating for Johnson & Johnson ( $JNJ ) to Buy, target set at 215 → 232.
0 · Reply
Suite510
Suite510 Dec. 11 at 8:22 PM
$JNJ $KVUE With over 67,000 lawsuits pending, the company is still trying to settle, but recent court decisions favor plaintiffs, and settlement discussions face challenges, with a major $8-10 billion settlement rejected earlier in 2025. Projecting $30B to 50B hope they can raise cash 💵 lol 😂
0 · Reply